Abbvie M19-939 (budigalimab phase 1 study)

Posted by •
Study typeSummaryInclusion CriteriaParticipation requirementsStatus
Randomised placebo-controlled studyPhase 2 of this international study is being conducted in Melbourne. Participants will receive 4 intravenous infusions of either budigalimab (a drug being studied to treat cancer known as an immune checkpoint blocker) or a placebo.
 
This study involves a closely monitored 12-week treatment interruption. There are strict criteria to restart HIV treatment to ensure participant safety.		· HIV+
· Adults 18-65 years
· On HIV treatment for >12 months
· plasma RNA < 50 copies/mL for > 6 months
· CD4 >500		Participants will receive 4 intravenous infusions of either budigalimab (a drug being studied to treat cancer known as an immune checkpoint blocker) or a placebo.
 
Participants will need to attend approximately 19 study visits over a 5-6 month period.
 
During the treatment interruption, participants are monitored every 1-2 weeks.		Currently recruiting

HIV Cure Community Partnership

Hivcure.com.au is the flagship project of the Australian HIV Cure Community Partnership to promote engagement between HIV cure researchers and people living with HIV. Members include NAPWHA, The Doherty Institute for Infection and Immunity, The Kirby Institute, The Alfred Hospital, Living Positive Victoria and Positive Women Victoria.

Must Read

Scroll to Top